二、董事会会议审议情况 证券代码：605198 证券简称：安德利 公告编号：2026-010 烟台北方安德利果汁股份有限公司 第九届董事会第七次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、董事会会议召开情况 烟台北方安德利果汁股份有限公司（以下简称"公司"或"本公司"）第九届董事 会第七次会议于 2026 年 3 月 24 日发出书面通知，于 2026 年 3 月 31 日以通讯表决的方 式召开。 本次会议由王安先生主持，应出席会议的董事 9 人，实际出席会议的董事 9 人。公 司部分高管人员列席会议。本次会议的召开及出席情况符合法律、法规、证券上市地交 易所上市规则及《公司章程》《公司董事会议事规则》的相关规定。 本议案已经公司第九届董事会战略委员会第二次会议审议通过，同意提交本次董事 会审议。具体议案内容详见本公司披露于上海证券交易所官网（www.sse.com.cn）的《关 于参与投资私募股权投资基金的公告》，公告编号（2026-012）。 3.关于修订《公司章程》并变更法定代表人的议案 与会董事经 ...

烟台北方安德利果汁股份有限公司 章 程 1 | 第一章 | 总则 | 3 | | --- | --- | --- | | 第二章 | 经营宗旨和范围 | 5 | | 第三章 | 股份和注册资本 | 5 | | 第四章 | 股份增减和回购 | 8 | | 第五章 | 股份转让 | 10 | | 第六章 | 股东和股东会 11 | | | 第七章 | 董事会 30 | | | 第八章 | 公司总裁及其他高级管理人员 43 | | | 第九章 | 公司秘书 45 | | | 第十章 | 财务会计制度与利润分配 46 | | | 第十一章 | 会计师事务所的聘任 51 | | | 第十二章 | 公司的合并、分立、增资和减资 | 52 | | 第十三章 | 公司解散和清算 54 | | | 第十四章 | 修改章程 57 | | | 第十五章 | 通知和公告 57 | | | 第十六章 | 附则 60 | | 烟台北方安德利果汁股份有限公司 章 程 第一章 总则 第一条 为维护烟台北方安德利果汁股份有限公司（以下简称"公司"）、股东和债权 人的合法权益，规范公司的组织和行为，根据《中华人民共和国公司法》（以下简 称"《公 ...

烟台北方安德利果汁股份有限公司（以下简称"公司"或"本公司"）于 2026 年 3 月 31 日召开第九届董事会第七次会议，审议通过了《关于修订<公司章程>并变更法 定代表人的议案》。本议案尚须提交公司 2025 年年度股东会审议。 一、本次《公司章程》修订情况 为规范公司的组织和行为，根据《中华人民共和国公司法》《上市公司章程指引》 等法律法规，结合公司实际情况，对《公司章程》中的相关条款进行相应修订，具体 修订如下： | | 修订后条文 | | --- | --- | | 现有条文 | （删减以删除线、修订以粗体及下划线的方式 | | | 呈现） | | 第一章 总则 | 第一章 总则 | | | 第四条 公司的法定代表人是公司董事长或者公 | | 第四条 公司的法定代表人是公司董事 | 司总裁，由公司董事会决议确定。担任法定代 | | | 表人的董事长或者总裁辞任的，视为同时辞去 | | 长。 | 法定代表人。 | | | 法定代表人辞任的，公司将在法定代表人 | | | 辞任之日起 30 日内确定新的法定代表人。 | 证券代码：605198 证券简称：安德利 公告编号：2026-013 烟台北方安德利 ...

Group 1: Biopharmaceutical Research - WuXi AppTec, as a global CRDMO leader, exceeded its revenue guidance for 2025, with a significant profit margin increase and a strong Tides business, reporting a 28% increase in backlog orders by the end of 2025, and expects a revenue growth of 18-22% in 2026 [1][3][4] - The company achieved a total revenue of RMB 45.46 billion in 2025, a year-on-year increase of 15.8%, and a net profit of RMB 19.15 billion, up 102.7% year-on-year, with adjusted Non-IFRS net profit rising by 41.3% [3][4] Group 2: Military Industry Research - The National Development and Reform Commission and the Ministry of Finance announced an optimization of the radio frequency occupation fee standards, which is expected to significantly reduce satellite internet frequency fees, accelerating the market penetration of satellite terminal applications [2][7][21] - The new fee structure will change the cost burden from end-users to satellite operators, facilitating the proliferation of satellite terminals and potentially lowering costs for high-frequency applications [8][21] Group 3: Home Appliance Research - TCL Electronics reported a strong performance in 2025, with revenue of HKD 114.58 billion, a year-on-year increase of 15.4%, and an adjusted net profit of HKD 2.51 billion, up 56.5% [9][10] - The company is focusing on high-end and global strategies, with a continuous increase in market share and an improved product structure leading to a significant enhancement in TV gross margins [11][12] Group 4: Food and Beverage Research - The demand for probiotics is expanding, driven by new channels like Douyin and emerging needs for weight loss, with a focus on the second-generation probiotic AKK, which is expected to accelerate market education and demand release [13][14] - The market for probiotic health products is projected to grow, with a 6% increase in scale to RMB 16 billion in 2025, and a notable 40% growth in GMV through Douyin [13][14]

Investment Rating - The investment rating for the company is "Accumulate" with a target price of 54.30 CNY [1][5]. Core Insights - The company achieved good performance in 2025, with sales volume increasing against the trend. The continuous expansion of production capacity is expected to enhance market share in the future, maintaining the "Accumulate" rating [2][11]. Financial Summary - Total revenue for 2025 is projected at 1,677 million CNY, representing a year-over-year increase of 18.3%. Net profit attributable to the parent company is expected to reach 330 million CNY, a growth of 26.7% compared to the previous year. The earnings per share (EPS) for 2025 is estimated at 0.99 CNY [4][12]. - The company’s net asset return rate (ROE) is forecasted to be 11.9% in 2025, with a price-to-earnings (P/E) ratio of 39.35 based on the latest diluted share capital [4][12]. Sales Performance - In 2025, the company achieved a sales volume of 125,600 tons, marking a year-over-year increase of 17.3%. Despite a decline in China's concentrated apple juice export volume to 380,000 tons due to international trade tensions, the company managed to grow its market share [11][12]. Capacity Expansion - The company is actively expanding its production capacity, having established a factory in Aksu, Xinjiang, and signed a strategic cooperation framework agreement for further investment in Yan'an, Shaanxi. Additionally, it has successfully acquired assets in Yantai and plans to invest in a juice processing production line in Huludao, Liaoning, which is expected to process 120,000 tons of apples and pears annually [11][12].

Investment Rating - The investment rating for the company is "Buy" [1][5]. Core Views - The company has shown strong performance in 2025, with sales growth despite market challenges. The continuous expansion of production capacity is expected to enhance market share in the future [2][11]. Financial Summary - Total revenue for 2025 is projected at 16.77 billion yuan, representing a year-over-year increase of 18.3%. Net profit attributable to shareholders is expected to reach 3.30 billion yuan, reflecting a growth of 26.7% [4][11]. - Earnings per share (EPS) for 2025 is estimated at 0.99 yuan, with projections for 2026 and 2027 at 1.04 yuan and 1.20 yuan respectively. The net asset return rate (ROE) is expected to be 11.9% in 2025 [4][12]. - The company maintains a price-to-earnings (P/E) ratio of 39.35 based on the latest diluted share capital [4][12]. Sales Performance - In 2025, the company achieved a sales volume of 125,600 tons, marking a year-over-year increase of 17.3%. The company also saw revenue from exports reach 1.155 billion yuan, up 14.84% year-over-year, while domestic sales revenue increased by 27.34% to 517 million yuan [11][12]. Capacity Expansion - The company is actively expanding its production capacity, with new facilities planned in regions such as Xinjiang and Shaanxi. This expansion is expected to further enhance the company's market share in the long term [11][12].

Market Strategy - The market is expected to maintain a volatile bottoming phase, with a focus on buying into high-growth performance sectors [5][11] - The overall market sentiment remains cautious due to external uncertainties, particularly geopolitical tensions in the Middle East, which may suppress market risk appetite [11] - Earnings reports due by the end of April are anticipated to significantly influence market trends, with high-valuation sectors facing potential pressure [11] Economic Insights - In January and February 2026, profits of large-scale industrial enterprises in China grew by 15.2%, totaling 10,245.6 billion yuan [17][18] - State-owned enterprises reported a profit of 3,665.6 billion yuan, a 5.3% increase, while private enterprises saw a 37.2% increase to 2,844.5 billion yuan [18] - The mining sector's profits increased by 9.9%, while the manufacturing sector's profits rose by 18.9% [18] Industry Dynamics - The semiconductor discrete device industry experienced a profit growth of 130.5% in the first two months of 2026 [28] - The U.S. has initiated a 337 investigation into TOPCon solar cell products, affecting several major Chinese manufacturers [26][27] - Guangdong province is optimizing housing provident fund policies to support housing consumption, particularly for families with multiple children [30] Company Updates - Rongchang Bio (688331.SH) reported a revenue of 3.251 billion yuan for 2025, a year-on-year increase of 89.36%, with a net profit of 710 million yuan [33] - Guotou Zhonglu (600962.SH) achieved a net profit of 41 million yuan in 2025, up 39.88% year-on-year [35] - Andeli (605198.SH) reported a net profit of 330 million yuan for 2025, reflecting a 26.71% increase [37] - Muyuan Foods (002714.SZ) reported a net profit of 15.487 billion yuan for 2025, a decline of 13.39% year-on-year due to falling pig prices [40] - Dingtai High-Tech (301377.SZ) plans to invest 5 billion yuan in a smart manufacturing headquarters project, with a revenue increase of 35.70% in 2025 [43][44]

香港交易及結算所有限公司及香港聯合交易所有限公司（「香港聯交所」）對本文件的內容 概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本文件全部 或任何部分內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 ANDRE Yantai North Andre Juice Co., Ltd.* 02218 二零二五年年度業績公佈 烟 台 北 方 安 德 利 果 汁 股 份 有 限 公 司（「 本公司 」）董 事 會 欣 然 宣 佈 本 公 司 及 其 附屬公司截至二零二五年十二月三十一日止之經審計業績。本公佈列載 本公司二零二五年年度報告全文，並符合香港聯合交易所有限公司證券 上市規則中有關年度業績初步公佈附載的資料之要求。本公司二零二五 年年度報告將於二零二六年四月八日在香港交易及結算所有限公司的網站 www.hkexnews.hk及本公司的網站www.andre.com.cn閱覽。 * 僅供識別 目錄 | 公司資料 | 2 | | --- | --- | | 財務摘要 | 3 | | 董事長報告書 | 5 | | 管理層討論及分析 | 10 | | 董事、監事及高級管理層 | 28 | | ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或 完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚賴該 等內容而引致的任何損失承擔任何責任 。 承董事會命 烟台北方安德利果汁股份有限公司 董事長 王安 中國烟台，二零二六年三月二十七日 於本公告日期，本公司執行董事為王安先生、張輝先生、王萌女士及王艷輝先生，非執行董事為劉宗 宜先生及張偉先生，獨立非執行董事為龔凡先生、王雁女士及王常青先生。 *僅供識別 1 海外監管公告 本公告乃烟台北方安德利果汁股份有限公司（「本公司」）根據《香港聯合交易所有限公司證券上市 規則》第 13.10B 條作出。 茲載列本公司於二零二六年三月二十七日在上海證券交易所網站刊發之《關於續聘 2026 年度會計師 事務所的公告》，僅供參閱。 证券代码：605198 证券简称：安德利 公告编号：2026-006 烟台北方安德利果汁股份有限公司 关于续聘 2026 年度会计师事务所的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或 完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚賴該 等內容而引致的任何損失承擔任何責任 。 海外監管公告 茲載列本公司於二零二六年三月二十七日在上海證券交易所網站刊發之《關於開展遠期結售匯的公 告》，僅供參閱。 承董事會命 烟台北方安德利果汁股份有限公司 董事長 王安 中國烟台，二零二六年三月二十七日 於本公告日期，本公司執行董事為王安先生、張輝先生、王萌女士及王艷輝先生，非執行董事為劉宗 宜先生及張偉先生，獨立非執行董事為龔凡先生、王雁女士及王常青先生。 本公告乃烟台北方安德利果汁股份有限公司（「本公司」）根據《香港聯合交易所有限公司證券上市 規則》第 13.10B 條作出。 *僅供識別 1 证券代码：605198 证券简称：安德利 公告编号：2026-008 烟台北方安德利果汁股份有限公司 关于开展远期结售汇业务的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ● 远期结售汇业务额度 ...